ZA94887B - A combination of neurotrophin and antibody directed toward myelinassociated neurite growth inhibitory protein promotes central nervous system regeneration - Google Patents
A combination of neurotrophin and antibody directed toward myelinassociated neurite growth inhibitory protein promotes central nervous system regenerationInfo
- Publication number
- ZA94887B ZA94887B ZA94887A ZA94887A ZA94887B ZA 94887 B ZA94887 B ZA 94887B ZA 94887 A ZA94887 A ZA 94887A ZA 94887 A ZA94887 A ZA 94887A ZA 94887 B ZA94887 B ZA 94887B
- Authority
- ZA
- South Africa
- Prior art keywords
- myelinassociated
- neurotrophin
- combination
- nervous system
- directed toward
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1635493A | 1993-02-11 | 1993-02-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA94887B true ZA94887B (en) | 1994-08-23 |
Family
ID=21776697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA94887A ZA94887B (en) | 1993-02-11 | 1994-02-09 | A combination of neurotrophin and antibody directed toward myelinassociated neurite growth inhibitory protein promotes central nervous system regeneration |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0634939A1 (en) |
| JP (1) | JPH07509002A (en) |
| AU (1) | AU5891394A (en) |
| CA (1) | CA2117889A1 (en) |
| IL (1) | IL108600A0 (en) |
| WO (1) | WO1994017831A1 (en) |
| ZA (1) | ZA94887B (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6576441B1 (en) | 1995-12-06 | 2003-06-10 | Sumitomo Pharmaceuticals Company, Limited | Semaphorin Z and gene encoding the same |
| WO1998011216A1 (en) | 1996-09-11 | 1998-03-19 | Sumitomo Pharmaceuticals Company, Limited | Novel semaphorin gene: semaphorin y |
| US6902730B1 (en) | 1996-10-09 | 2005-06-07 | Sumitomo Pharmaceuticals Company, Limited | Semaphorin gene: Semaphorin W |
| CA2190418A1 (en) * | 1996-11-15 | 1998-05-15 | Zhi-Cheng Xiao | Neuron and neural tumor growth regulatory system, antibodies thereto and uses thereof |
| AU4964097A (en) | 1996-11-15 | 1998-06-10 | Sumitomo Pharmaceuticals Company, Limited | Novel semaphorin genes (i) |
| EP0878480A1 (en) * | 1997-05-14 | 1998-11-18 | H.W. Prof. Dr. Müller | A method for the improvement of neuronal regeneration |
| SE9901428D0 (en) * | 1999-04-21 | 1999-04-21 | Karolinska Innovations Ab | Amphibodies |
| AU784349C (en) | 2000-01-12 | 2006-09-28 | Yale University | Nogo receptor-mediated blockade of axonal growth |
| NZ525422A (en) | 2000-10-06 | 2006-09-29 | Biogen Idec Inc | Isolated polynucleotides comprising a nucleic acid which encodes a polypeptide which modulates axonal growth in CNS neurons |
| CA2549000A1 (en) * | 2003-12-16 | 2005-06-30 | Children's Medical Center Corporation | Method for treating neurological disorders |
| US8912144B2 (en) | 2003-12-16 | 2014-12-16 | Children's Medical Center Corporation | Method for treating stroke via administration of NEP1-40 and inosine |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100196540B1 (en) * | 1988-11-04 | 1999-06-15 | 마틴 이. 샤브 | Neurite growth regulatory factors |
| GR1000980B (en) * | 1989-08-30 | 1993-03-31 | Max Planck Gesellschaft | Neurotrophin -3,a novel neurotrophic factor related to nerve growth factor and brain derived neurotrophic factor |
| WO1993000427A2 (en) * | 1991-06-24 | 1993-01-07 | Erziehungsdirektion Of The Canton Zurich | Neurite growth regulatory factors |
| JP2008027291A (en) * | 2006-07-24 | 2008-02-07 | Hitachi Ltd | Storage device and data protecting method |
-
1994
- 1994-02-08 AU AU58913/94A patent/AU5891394A/en not_active Abandoned
- 1994-02-08 EP EP94905206A patent/EP0634939A1/en not_active Withdrawn
- 1994-02-08 CA CA002117889A patent/CA2117889A1/en not_active Abandoned
- 1994-02-08 WO PCT/IB1994/000011 patent/WO1994017831A1/en not_active Application Discontinuation
- 1994-02-08 JP JP6517851A patent/JPH07509002A/en active Pending
- 1994-02-09 IL IL10860094A patent/IL108600A0/en unknown
- 1994-02-09 ZA ZA94887A patent/ZA94887B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPH07509002A (en) | 1995-10-05 |
| IL108600A0 (en) | 1994-05-30 |
| CA2117889A1 (en) | 1994-08-18 |
| EP0634939A1 (en) | 1995-01-25 |
| WO1994017831A1 (en) | 1994-08-18 |
| AU5891394A (en) | 1994-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB9624256D0 (en) | Watere treatment process and system | |
| EP0766651A4 (en) | Controlled denitrification process and system | |
| EP0785276A4 (en) | Modification of peptide and protein | |
| AU1875692A (en) | Exhaust treatment system and method | |
| IL109268A0 (en) | Pattern recognition method and system | |
| AU4638393A (en) | Process for hemoglobin extraction and purification | |
| HUP9900935A3 (en) | Antifungic and antibacterial peptide and process for preparation | |
| EP0775711A4 (en) | Peptide having antithrombotic activity and process for producing the same | |
| ZA94887B (en) | A combination of neurotrophin and antibody directed toward myelinassociated neurite growth inhibitory protein promotes central nervous system regeneration | |
| HUP9900323A2 (en) | Recombinant protein having bacteriophage endosialidase enzymatic activity | |
| SG79882A1 (en) | Protein having tpo activity | |
| EP0559098A3 (en) | Engine control system and method | |
| EP0593663A4 (en) | Method and assay system for neurotrophin activity | |
| AU1996599A (en) | Long-term survival and regeneration of central nervous system neurons | |
| AU4362696A (en) | Growth inhibitory peptide and methods of using same | |
| EP0838432A4 (en) | Sink-and-float body for purification and purificator | |
| IL109280A0 (en) | Neurotrophins for treatment of depression | |
| EP0781297A4 (en) | Cytotactin derivatives that stimulate attachment and neurite outgrowth, and methods of making and using same | |
| EP0833904A4 (en) | Fibroblast growth factor-14 | |
| SG52769A1 (en) | Regeneration of aromatization catalysts | |
| EP0921803A4 (en) | Methods for preventing and treating pestivirus infection and associated diseases | |
| GB2301783B (en) | Process and system for filtering polyamide oligomers | |
| EP0866717A4 (en) | Oligodendrocyte-specific protein and method for treating disease | |
| ZA963417B (en) | Methods of preventing neuron degeneration and promoting neuron regeneration | |
| PL311885A1 (en) | Protein of tpo activity |